Psilocybin as a Disease-Modifying Drug - A Salutogenic Approach in Psychiatry
We invite you to an engaging discussion about the article "Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in Psychiatry" with Moritz Spangemacher.
Moritz Spangemacher is a resident physician at the Central Institute of Mental Health in Mannheim. He works in the Molecular Neuroimaging department led by Prof. Gerhard Gründer. His focus lies in clinical psychiatry and the research on psychopharmacological interventions. He worked as a psychotherapist in the EPisoDE study, which is a Phase II study that investigated the safety and efficacy of psilocybin in treatment-resistant depression. Furthermore, he investigates potential blood biomarkers for treatment response in the course of ketamine treatment. He completed his medical studies at Ludwig Maximilians University (LMU) in Munich and previously studied philosophy at Saarland University.
The paper proposes and via narrative review defends the hypothesis that psychotherapy augmented with psilocybin is a salutogenetic form of therapy for disorders like (treatment-resistant) depression, substance use disorder, end-of-life-anxiety and more. Salutogenesis means that the roots of the disorder, rather than the mere symptoms, are addressed, leading to long-lasting positive outcomes. The paper also gives a brief overview of the history, mechanisms of action, adverse effects, challenges in research and open questions regarding psychedelically assisted psychotherapy.
The discussion will be in English and anyone can participate.
The English version of the article will be available soon: https://www.aerzteblatt.de/int/archive/article/242252
We look forward to your participation and an insightful conversation!
Join us in